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A cardiolipin-  and  protease-activated  protein kinase 
(PAK) has been isolated from cytoplasmic  extracts  of  rat 
liver. The enzyme  (PAK-1) phosphorylates  the  ribosomal 
protein  S6-(229-239)  peptide  analogue  and can be acti- 
vated by limited proteolysis. Partial amino acid se- 
quences of tryptic  peptides  derived from  both the puri- 
fied 116-kDa  PAK-1 holoenzyme  and its active catalytic 
fragment reveal that the catalytic domain is most re- 
lated (50458% identity) to the protein kinase C family. 
PAK-1 has protein and peptide substrate specificities 
distinct from those  of  known  protein  kinase C isoforms 
and is insensitive to inhibition by the protein kinase 
C-a-(19-31)  pseudosubstrate  peptide.  Phosphatidyl- 
serine, diacylglycerol,  and  phorbol ester do not  activate 
PAK-1 toward the S6 peptide  substrate.  However,  other 
acidic phospholipids, the most effective being cardio- 
lipin, activate PAK-1 to a  similar extent as trypsin. The 
PAK-1 catalytic activities generated  through activation 
by cardiolipin or limited proteolysis were kinetically 
similar,  with K,,, values  of  3.6  and  3.4 px, respectively,  for 
the  564229-239)  peptide  substrate.  However,  differences 
were  observed in the catalytic activities with  protamine 
sulfate and the glycogen synthase-(1-12) peptide ana- 
logue as substrates. It was concluded that PAK-1 is a 
phospholipid-regulated  protein kinase with a  primary 
structure,  substrate  specificity,  and  mechanism of regu- 
lation in vitro distinct from those of any  known  member 
of  the  protein  kinase C superfamily. 
Ribosomal  protein S6 is phosphorylated at multiple  sites (e.g. 
Refs. 1-3) in mammalian  cells in response  to  growth-promoting 
and mitogenic stimuli (4-9). The anabolic responses can be 
largely  attributed  to a unique  class of S6-specific protein  ki- 
nases  activated  by  direct  phosphorylation  on serine and  thre- 
onine  residues  (reviewed in Ref. 8). There are indications that 
other  protein  kinases,  including  protein  kinase C (PKC)’ and a 
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class of protease-activated  protein  kinase (PAK), can also con- 
tribute to insulin- and growth factor-dependent S6 phospho- 
rylation  responses,  either  directly  or  indirectly  via the mitogen- 
activated protein kinases (7, 10). Several PAKs have been 
described  during  the  past  decade that are capable of phospho- 
rylating  ribosomal  protein S6 and that have  been  implicated  in 
anabolic  regulation of mammalian  cells (11-141, but most  have 
not  been  characterized  structurally. The contribution of PAKs 
to the overall growth responses has been dificult to assess, 
partly  because of the uncertainty of their  relationship  with  the 
PKC isoenzymes (e.g. Ref. 151, which  can  also  be  activated  by 
mild  proteolysis (16-18) and which  have  similar  phosphoryla- 
tion  site  specificities (18-20). 
The aim of this  study  was  to  use  proteolytic  activation  in 
vitro (11, 21) as a strategy  for  identifying  and  further  charac- 
terizing  potentially  novel  protein  kinases  in rat liver  extracts 
capable of phosphorylating a peptide analogue of ribosomal 
protein S6 (e.g. Refs. 14 and 20). The mild  conditions of prote- 
olysis  employed  were  designed  to be effective in  the removal of 
protein  kinase  regulatory  domains  containing  autoinhibitory  or 
pseudosubstrate inhibitory sequences without affecting the 
functional  integrity of their  catalytic  domains (11, 22-24). A 
major form of hepatic PAK activity (referred to as PAK-11, 
previously  shown  to  phosphorylate  ribosomal  protein S6 (14, 
20),  was  purified and found  to  be  activated  by  cardiolipin,  but 
was  determined  to  be  structurally  distinct  from  the  previously 
described  PKCs. 
EXPERIMENTAL. PROCEDURES 
MateriaZ~-[y-~~PlATP was obtained from Bresatec Ltd. (Thebarton, 
Australia); chromatographic supports were  from Pharmacia LKEl 
(Uppsala, Sweden); TPCK-treated trypsin was  from  Worthington; alkyl- 
ated trypsin was  from  Promega; ethanediol (Analar) was from  Merck 
BDH; and protein substrates, phospholipids, diacylglycerol (diolein), 
protease inhibitors, 12-0-tetradecanoylphorbol-13-acetate (phorbol es- 
ter),  and Brij-35  from Sigma. Synthetic peptide analogues (see Footnote 
1) were synthesized (as C-terminal amides) on an Applied  Biosystems 
Model  430A peptide synthesizer as previously  described (19, 24). Thre- 
onine-Sepharose 4B was prepared as described by Kikkawa et al. (25). 
Protamine-CH-Sepharose 4B (2.1 mg of protamine/ml of resin) was 
prepared from activated CH-Sepharose 4B and protamine sulfate as 
described by the manufacturer (Pharmacia LKB). PKC (mixed  isoen- 
zymes)  was prepared from rat brain as described by House et al. (19) 
and stored at -70 “C in 50% glycerol and 0.05% (v/v)  Triton X-100. 
Purification of PAKs from Rat Liuer-PAKs were freshly prepared 
from the livers of 4-8-month-old  Buffalo rats fed ad libitum; all opera- 
Arg-Ala-Cys;  GS-(1-12), synthetic peptide analogue based on skeletal 
muscle glycogen synthase sequence, residues 1-12, Pro-Leu-Ser-kg- 
Thr-Leu-Ser-Val-Ala-Ala-Lys-Lys; EGFR-(650-658), epidermal growth 
factor receptor analogue, residues 650-658, Val-Arg-Lys-Arg-Thr-Leu- 
Arg-Arg-Leu; H4-(4349), histone H4 analogue, residues 43-49, Val- 
Lys-Arg-Ile-Ser-Gly-Leu; PKC-a-(19-31) pseudosubstrate inhibitor 
peptide, Arg-Phe-Ala-Arg-Lys-Gly-Ala-Leu-Arg-Gln-Lys-Asn-Val; PKI- 
Thr-Thr-Tyr-Ala-Asp-Phe-Ile-Ala-Ser-Gly-Arg-Thr-Gly-Arg-Arg-Asn- 
(4-24),  CAMP-dependent protein kinase inhibitor, residues 4-24, Glu- 
Ala-Ile-His-Asp. 
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tions  were  performed at 4 "C, and  the  liver  post-microsomal  (150,000 x 
g) supernatant fraction was chromatographed on DE52 as described 
previously  (14).  Fractions  containing  trypsin-activated  protein  kinase 
activity  (14)  were pooled, dialyzed uersus buffer  B (15 mM potassium 
phosphate,  pH  6.4, 1 mM EDTA, 2 mM EGTA, 10 mM 2-mercaptoetha- 
nol, 2 mM benzamidine, and 0.25 mM PMSF),  and  loaded  onto  a CM- 
Sephadex  column (50 mYlOO g of tissue)  equilibrated  in  the  same buffer. 
The  column  was  washed  with 5 column  volumes of buffer  B  and  eluted 
with an 8-volume  linear  gradient of 0-0.4 M KCl; 6-ml  fractions  were 
collected. 
The PAK-1 fraction  from  CM-Sephadex  was  adjusted  to  20 mM Tris- 
HCl, pH 7.5, plus 1 M ammonium sulfate and loaded onto phenyl- 
Sepharose 4B (1 ml of resid15  mg of protein  loaded)  equilibrated in 
buffer C (20 mM Tris-HC1, pH 7.5, 1 mM EDTA, 2 mM EGTA, 10 mM 
2-mercaptoethanol,  2 mM benzamidine,  and 0.25 mM PMSF)  containing 
1 M ammonium  sulfate.  The  column  was  then  washed successively with 
10-column volume  batches of buffer  C  containing  1, 0.5, 0.2, or 0.1 M 
ammonium sulfate or no ammonium sulfate and finally with 10 vol- 
umes of buffer  C  containing 50% (v/v) ethanediol.  The  latter  two  washes 
containing PAK-1 activity  were pooled, dialyzed  against  buffer  D  (buffer 
C containing 10% ethanediol, 0.01% (v/v) Brij-35, and 50 mM NaCl), 
loaded onto a 5-ml threonine-Sepharose 4B column equilibrated in 
buffer D, and eluted with a 120-ml 0.05-1 M NaCl linear gradient. 
Column fractions (2 ml) containing the peak of PAK-1 activity were 
pooled, diluted 1:l  with buffer D, and loaded onto a protamine-CH- 
Sepharose  4B  column (5 ml)  equilibrated  in  buffer  D  plus 0.2 M NaC1. 
The  column  was  washed  with  4  volumes of the  same  buffer followed by 
a  150-ml  linear  gradient of  0.2-2 M NaCl. The column fractions  (2  ml) 
containing PAK-1 activity  were pooled, dialyzed against buffer D, 
loaded onto a Pharmacia Mono Q 5/5HR column equilibrated in the 
same buffer, and  chromatographed  using a Pharmacia  FPLC  system. 
The  single  peak of PAK-1 activity  was  eluted  with  a  linear  gradient of 
0.05-0.5 M NaCl(10 d m l )  in  buffer D; 0.5-ml fractions  were collected. 
Protein  Kinase and Protein Assays-Column fractions  were  activated 
by mild  trypsinolysis  in  the  presence of PMSF-treated BSA (0.8 mg/ml) 
as described previously (Ref. 14; see also Refs. 7, 11, and 26). The 
resultant  peptide  kinase  activity  was  assayed  with 30 PM S6-(229-239) 
substrate  in a reaction  mixture (60 p1) containing 20 mM Tris-HC1, pH 
7.6, 5 mM MgCl,, 0.2 mM ATP (10-100 cpdpmol), 40 mM KCl, 1 mM 
EGTA, 1 mM EDTA, 1 mM dithiothreitol,  0.18 mg/ml PMSF-treated BSA, 
and 2  p~ PKI-(4-24) (27) for 5-15 min at 30 "C. The  incorporation of 
32P-labeled  phosphate  into  peptides  was  determined  using the  What- 
man P-81 paper binding method (28). Protein kinase activities were 
assayed  under  the  same  reaction  conditions, except that  the S6 peptide 
substrate was replaced by protamine sulfate a t  0.5 mg/ml or other 
proteins a t  1 mg/ml as indicated.  The  32P  radioactivity  incorporated  into 
protamine was also determined by the P-81 paper binding method, 
while  other  protein  substrates  were  assayed  with acid precipitation on 
Whatman No. 1 paper  using  15% (w/v) trichloroacetic  acid. 32P radio- 
activity  was  determined by Cerenkov  radiation  using  a  liquid  scintilla- 
tion  counter.  For  kinetic  experiments, PAK activity  was  adjusted so that 
the  reaction  rates  were  constant  with  respect  to  time for all  substrate 
concentrations employed. PAK-1 activity  was  adjusted so that no more 
than 10% of the peptide substrate  was  consumed. K, and V,, values 
were  determined by fitting  data to  the Michaelis-Menten  equation as 
described  previously  (24). 
PKC activity  was  assayed  using  30  p~ S6-(229-239) as substrate  (19) 
as described above for  peptide  kinase  activity  with or without  100 pg/ml 
phosphatidylserine and 0.5 mM CaC1,. The effects of cardiolipin and 
other  phospholipids  were  investigated  using  the  same  reactions mix- 
ture  as described for peptide kinase activity (see above), except that 
soybean  trypsin  inhibitor  (0.1  mg/ml)  was  substituted for PMSF-treated 
BSA, and  the  assays  were  carried  out  in  the  presence  and  absence of 
sonicated  phospholipid  dispersions at the concentration specified in  the 
text. 
Standard procedures  were  used for Bradford  protein  determinations 
(29) (BSA as  standard), SDS-PAGE using 7.5% resolving  and 4% stack- 
ing  gels (301, and  staining  with  either Coomassie Brilliant  Blue  (30) or 
silver  stain  (Bio-Rad)  (31).  Stained  protein  bands  were  quantitated by 
densitometry  using  a  Molecular  Dynamics  laser  densitometer. 
Isolation ofPM-1  and  PKCActiue  Fragments-Preparations of phen- 
yl-Sepharose-purified PAK-1 or brain PKC were  dialyzed  against  buffer 
E (50 mM Tris-HC1, pH 8.0, 25 mM NaC1, 5 mM MgCl,, 2 mM EGTA, 10 
mM 2-mercaptoethanol, 10% ethanediol,  and 0.01% (v,v) Brij-35), and 
after  dialysis,  PMSF-treated BSA was  added  to 0.5 mg/ml. The  protein 
fraction  was  digested  with  TPCK-treated  trypsin (1:100, w/w) for 3 min 
a t  30 "C. The  reaction  was  stopped  with  32 x (w/w) excess of soybean 
trypsin  inhibitor  and  0.25 mM PMSF  (on ice). The  digest  was  loaded  onto 
a  5-ml S6 peptide  affinity column ([Cy~~~"]S6-(229-240) coupled to di- 
vinyl sulfone-activated  Sepharose)  equilibrated  with  buffer  E  contain- 
ing 10 pg/ml soybean  trypsin  inhibitor.  After  washing  with 5 volumes 
of buffer E (plus soybean trypsin inhibitor), the column was eluted 
with a 150-ml linear  gradient of 0.025-0.525 M NaCl.  Fractions  contain- 
ing  protein  kinase  activity  were pooled, dialyzed uersus buffer E over- 
night,  and  then  loaded  onto a Mono Q 515HR column  in  buffer  E  using 
a Pharmacia  FPLC  system,  and  the  proteins  were  eluted  at 1 mYmin 
with  a 45-ml linear  gradient of 0.05-0.5 M NaCl;  0.5-ml  fractions  were 
collected. 
Amino Acid Sequence Analysis-Purified PAK-1 (post-Mono Q frac- 
tion) or its  catalytic  fragments  were  dialyzed  against  10 mM NH,HCO, 
buffer containing 0.02% SDS and 20 mM 2-mercaptoethanol for 3 h, 
concentrated 50-fold, and  alkylated  with  2  pl of 4-vinylpyridine for 3  h 
at 37 "C. The protein was precipitated with 9 volumes of ethanol a t  
-20 "C and digested with TPCK-treated trypsin ( l : l O ,  w/w) in 0.1 M 
NH,HCO,, 0.1 mM CaCl, buffer for 24  h a t  37 "C. The  tryptic  peptides 
were  separated by reversed-phase  HPLC on a  5-pm  Waters  Delta-Pak 
ODS column  (2.1 x 150  mm) developed with  a  linear  gradient of 0-50% 
acetonitrile (0.5%/min) in aqueous 0.1% trifluoroacetic acid at 0.2 ml/ 
min.  In-gel  digests of PAK-1 were  performed by excising  the Coomassie 
Blue-stained  116-kDa  polypeptide  band from SDS-polyacrylamide  slab 
gels  (1.5  mm  thick),  washing  in deionized water (5 x 1 mlj for 2 h,  and 
drying  the gel piece under  vacuum.  The  dried  gel piece was  hydrated  in 
0.4 ml of 0.1 M NH,HCO, containing  0.1 mM CaCl, and 1 pg of alkylated 
trypsin (Promega) and incubated for 22 h at  37 "C. The digest was 
clarified by centrifugation before separating the tryptic peptides by 
reversed-phase  HPLC  using  the  Waters  Delta-Pak ODS column in con- 
junction  with  acetonitrile  gradient  elution  as  described above. Peptides 
were  sequenced on an  Applied Biosystems Model 477A Sequencer  with 
on-line phenylthiohydantoin-derivative analyses. 
RESULTS 
Resolution of Liver PAK Activities on CM-Sephadex-Liver 
PAK activities  were  assayed with  the peptide  analogue of the 
ribosomal S6-(229-239) sequence,  containing two of the  insu- 
lin- and growth  factor-dependent  phosphorylation sites (3,  32, 
33). Three broad peaks of  PAK activity  were resolved following 
chromatography on CM-Sephadex (Fig. l), with peaks eluting 
at  -100 mM KC1 (termed PAK-1) and 250 mM KC1 (PAK-2) (Fig. 
la) .  PAK-2 activity was only apparent when  a range of protease 
inhibitors were included in  the  initial liver extraction buffer 
(see "Experimental Procedures"), and even with  these precau- 
tions, the  relative proportions of the PAK activities  varied be- 
tween  experiments (compare  activity profiles in Fig. l ,  a and b). 
A peak of PKC activity eluted on the  leading edge of the peak of 
PAK-1 activity  (see Fig. 1 legend); this coincided with  the only 
discrete  peak of trypsin-dependent activity observed with the 
histone H1-rich Sigma Type 111-S histone substrate, a sub- 
strate preferred by the PKCs (Fig. la)  (17, 34). 
Differential Sensitivities of PAlCs to PKC  Pseudosubstrate In- 
hibitor Peptide-The PAK activities resolved on CM-Sephadex 
exhibited  differential sensitivities  toward  the PKC pseudosub- 
strate inhibitor  peptide (PKC-~~(19-31)) (24). The  later  eluting 
PAK-2 activity  was  strongly  inhibited, while the major compo- 
nent of the PAK-1 activity peak was  relatively unaffected by the 
inhibitor peptide (Fig. lb).  The inhibitor-sensitive component 
of the  leading edge of the PAK-1 activity  peak coincided with 
the peak of phosphatidylserine/Ca2+-dependent (data not 
shown) and histone H1 (Fig. la)  kinase activities. 
Purification of Liver Pm-1"Hydrophobic  interaction chro- 
matography of the CM-Sephadex pooled fractions of PAK-1  ac- 
tivity on phenyl-Sepharose resolved the major PAK-1 activity 
from several contaminating protein kinases, including the 
phosphatidylserine/Ca2+- and CAMP-dependent protein kinase 
activities (data not shown). The PAK-1 recovered from phenyl- 
Sepharose  was  further purified by successive chromatographic 
steps on threonine-Sepharose 4B, protamine-CH-Sepharose 
4B, and Mono Q (data not  shown).  The specific activity (Table 
I) and SDS-PAGE analyses (Fig. 2) showed that  the protamine- 
CH-Sepharose step was the most effective in removing extra- 
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FIG. 1. CM-Sephadex  chromatography of hepatic  protein ki- 
nases. a, pooled fractions eluted from DE52-cellulose  containing PAK 
and PKC activities were  chromatographed on CM-Sephadex,  and the 
column fractions were assayed for protein kinase activities with the 
S64229-239)  peptide (0, 0) or histone Type 111-S (W, 0) as substrate 
(see “Experimental  Procedures”). Assays with (0, W) and  without (0,O) 
trypsin treatment determined PAK activities. The  position marked with 
an arrow as PKC denotes  the  position of elution of phosphatidylserine/ 
Ca2+-dependent S6-(229-239) peptide kinase (data not  shown). Protein 
kinase activities were assayed in the presence of 2 PM PKI-(4-24) (28). 
b,  chromatography of the post-DE52-cellulose preparation of PAK ac- 
tivities on CM-Sephadex was carried out as described for a. Column 
fractions were assayed for S6-(229-239) kinase  activity  with (0, A) and 
0) of 40 PM PKC-a-(19-31)  synthetic peptide. 
without (0, A) trypsin  activation in the presence (A, A) and absence (0, 
neous protein. The  final Mono Q step yielded a  single peak of 
PAK-1 activity  containing a highly purified preparation of a 
116-kDa polypeptide as determined by SDS-PAGE (Fig. 2, lane 
6). This estimate correlated with the apparent M ,  of native 
PAK-1 of -100,000 determined by gel permeation chromatog- 
raphy on Sephacryl S-200 (data  not shown). 
Purification of Proteolytically Generated Catalytic  Frag- 
ment(s) of PAK-1-The active fragment(s) of PAK-1 was gener- 
ated by mild trypsinolysis of the PAK-1 recovered from phenyl- 
Sepharose  under  the  same digestion  conditions employed in  the 
PAK assay; SDS-PAGE analyses of the digestion  products 
showed that -70%  of the 116-kDa PAK-1 polypeptide had been 
cleaved, generating  fragments  in  the 43-55-kDa range  (data 
not shown). The active catalytic fragments were purified by 
sequential chromatography on [Cy~~*~]S6-(229-240) peptide- 
Sepharose affinity (data not shown)  and Mono Q (Fig. 3) col- 
umns.  The  catalytic  fragment of PAK-1 eluted a t  a higher  salt 
concentration than  the active fragment(s) of brain PKC (re- 
ferred  to  as PKM (17)) generated by the  same proteolytic di- 
gestion protocol from both  the peptide  affinity (data  not shown) 
and Mono Q (Fig. 3B) columns. SDS-PAGE analysis of Mono Q 
column fractions showed that the major PAK-1 polypeptide 
that copurified with  the  S6 peptide kinase activity was a 55- 
kDa species, with  lesser  quantities of 51- and 43-kDa species 
(Fig. 3A). All three species were distinct from any of the 
polypeptides  associated with  the PKM activity (545  kDa)  (Fig. 
3B).  The  intensity of silver-stained bands  determined by den- 
sitometry compared with known protein  standards provided an 
estimate of the  amount of protein  in  the  final  peak  fractions f 
PAK-1 fragments. On this basis, it was estimated that the 
specific activity of the purified PAK-1 fragments  was -5 pmol 
of 32P, transferred  per min/mg of enzyme with  the S6-(229-239) 
substrate.  This  high specific activity is  within  the  same  order of 
magnitude of the specific activities of CAMP-dependent protein 
kinase  and PKC with  their  preferred peptide substrates. 
Kinetic Properties of PAK-1-The kinetic  properties of the 
intact  preparations of PAK-1 were  distinct from those of the 
proteolytically generated activity. The ATP substrate K,,, for the 
holoenzyme was  an  order of magnitude  higher  than that ob- 
served for the  isolated  catalytic  fragment (K,,, = 200 and  12 VM, 
respectively). The K,,, for the purified preparations of the ho- 
loenzyme with  the S6-(229-239) substrate  was  estimated  to be
110 p ~ ,  although some preparations of PAK-1 exhibited bipha- 
sic  Lineweaver-Burk  plots with  the  peptide  substrate  (data not 
shown), suggesting two catalytic activities with approximate 
K,,, values of 3 VM (minor component) and 110 p~ (major com- 
ponent).  The low K,,, value  approximated  to  the K, value of 3.4 
p~ determined for the  trypsin-activated form of PAK-1 with  the 
same  substrate (201, suggesting that the low K,,, component of 
the holoenzyme preparations  relates  to an activated form of the 
enzyme. 
The V,, values  estimated for the PAK-1 holoenzyme prepa- 
rations  with  and  without  trypsin  activation were  3.1 and  1.7 
pmol/min/mg of PAK-1 protein, respectively, for the S6-(229- 
239) substrate. However, precise measurement of the V,, data 
was  made difficult by peptide substrate  inhibition of the  tryp- 
sin-activated enzyme a t  high substrate concentrations (data 
not shown), similar  to  the  inhibition of PKC by the myristyl- 
ated  alanine-rich C-kinase substrate peptide analogue (35). 
Intact PAK-1 was  also able to phosphorylate the  protamine 
sulfate  substrate  without  trypsin  activation (Table 11). The  fa- 
vorable kinetic properties of the enzyme with  this  substrate 
(K,,, = 3.6 p ~ ;  V,, = 1.5 pmol/min/mg) resembled those of the 
proteolytically activated enzyme with  the  S6 peptide substrate. 
Surprisingly, however, the purified  active catalytic  fragment of 
PAK-1 exhibited only a relatively low level of protamine  kinase 
activity (Table 11). Consistent  with  this  finding  was  the inhib- 
itory effect of the  trypsin  pretreatment on the  protamine  kinase 
activity of the whole PAK-1 preparations (Table 11). The resid- 
ual  protamine  kinase activity  associated with  trypsin-treated 
PAK-1 preparations  was  at  least  partially  attributable  to  the 
residual  intact 116-kDa PAK-1 that survived  the  limited pro- 
teolysis (as discussed above). 
Phospholipid Regulation of PAK-1-Intact preparations of 
purified PAK-1 exhibited basal  S6  peptide  kinase activity a t  30 
p~ S6-(229-239) substrate,  usually corresponding to 20-25%  of 
the  activity following trypsin  treatment.  The  basal activity was 
not appreciably enhanced by the  addition of Caz+/calmodulin, 
CAMP, or various combinations of phosphatidylserine, 12-0- 
tetradecanoylphorbol-13-acetate, diacylglycerol, and Ca2+ un- 
der conditions effective for activation of brain PKC (data  not 
shown). Phosphatidylethanolamine  and phosphatidylcholine 
also had no effect on PAK-1 activity (Fig.  4). However, cardio- 
lipin  activated  the enzyme to  a similar  extent  as  trypsin  (see 
Fig.  4 legend),  generating a low K,,, form of the enzyme both 
with  respect to  ATP (K,  = 20 p ~ )  and S6-(229-239) (K,,, = 3.6 
p ~ )  substrates.  Thus,  the cardiolipin- and  protease-activated 
forms of PAK-1 were judged  to be kinetically similar  to  both  the 
S6-(229-239) peptide and ATP substrates.  Other acidic phos- 
pholipids, with  the exception of phosphatidylserine, also acti- 
vated PAK-1, but from the dose-response  curves, it  was  appar- 
ent that the enzyme was most sensitive  to  activation by 
cardiolipin  (Fig.  4).  A characteristic  feature of the cardiolipin 
dose-response curve was the inhibition by higher concentra- 
tions of the lipid, with  the  maximum effect being  observed at 10 
pg/ml. Higher concentrations of phosphatidylglycerol, phos- 
phatidylinositol, and  phosphatidic acid  were required for maxi- 
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TABLE I 
Purification of PAK-1 from rat  liver 
PAK-1 was  purified from the post-150.000 x g cytosol of 30 rat livers  to  apparent homogeneity. PAK-1 activity  was  assayed as described under 
"Experimental  Procedures"  and is expressed as  the S64229-239) peptide  kinase  activity  obtained  with  trypsin  activation. 
Purification  step Volume Protein Activity Specific activity Yield" Purification 
ml mglml  n ollmin  nmollminlmg % -fold 
DE52 250 12.3 426 
CM-Sephadex 285 0.4 619  5.4 100 1 
Phenyl-Sepharose  59.5 0.25 241 16.2 39  3 
Threonine-Sepharose 26 0.2 158 30.4 25 5.6 
Protamine-CH-Sepharose 24.3 0.002h  84  1728 13 320 
Mono Q 4.5 0.003h  33 2444 5 452 
0.1 
Yield  of  PAK-1 is expressed as  a percentage of the CM-Sephadex pool (100%). 
The  protein  concentrations of protamine-CH-Sepharose  and Mono Q pools were  estimated by densitometry of silver-stained PAK-1 in 7.5% 
SDS-polyacrylamide  electrophoretograms  using a standard  curve  generated from a  separate  gel loaded with 1-500 ng of  BSA. 
kDa 1 2 3 
205 - 
4 5 6 
116- 
97- 
66- 
45 - 
FIG. 2. SDS-PAGE analysis of PAK-1 fractions  during  purifica- 
tion. S64229-239) kinase  peak  activity  fractions  obtained a t  each step 
during  purification of PAK-1 from the post-DE52-cellulose pool were 
analyzed by SDS-PAGE using 7.5% polyacrylamide gels and silver 
staining.  The  samples  loaded  were as  follows: lane 1,30 pg of post-DE52 
fraction; lane 2,19 pg of post-CM-Sephadex fraction (Fig. 1); lane 3,6.3 
pg of post-phenyl-Sepharose  fraction; lune 4, 5 pg of post-threonine- 
Sepharose  fraction; lane 5,0.3  pg of post-protamine-CH-Sepharose frac- 
tion; lane 6,0.4  pg of post-Mono Q fraction.  The  standard  protein  mark- 
ers used  were myosin (205  kDa),  P-galactosidase (116 kDa), 
phosphorylase  (97  kDa), BSA (66  kDa),  and  ovalbumin  (45 kDa). 
mal activation, and  there  was relatively little evidence of in- 
hibitory effects of these lipids at even higher concentrations 
(Fig. 4). In all cases, phospholipid activation of PAK-1 was 
independent of calcium, phorbol ester, or diacylglycerol (data 
not shown). 
Substrate Specificities of PAK-1-Appreciable differences 
were observed in  the  substrate preferences exhibited by the 
purified catalytic fragments of PAK-1 and brain PKC for a 
range of protein and peptide substrates (Table 11). The most 
pronounced differences were observed with  the  synthetic pep- 
tide analogue of the glycogen synthase N-terminal sequence 
(based on residues 1-12), Pro-Leu-Ser-Arg-Thr-Leu-Ser-Val- 
Ala-Ala-Lys-Lys (191, and  the EGFR-(650-658) analogue of the 
epidermal growth factor  receptor  sequence, Va1650-Arg-Lys-Arg- 
Thr-Leu-Arg-Arg-Le~~~~  (19) (Table 11). The glycogen synthase 
analogue was  the  best of all substrates  tested (comparisons 
made at a  peptide  concentration of 100 PM) for the catalytic 
fragment of  PAK-1. This analogue  was a 6-fold better  substrate 
than for PKM, apparently reflecting  a difference in V,, as  the 
K,,, for PAK-1 of 32 PM was  higher  than  that for brain PKC (4.1 
1"; see Ref. 19). Conversely, the EGFR4650-658) peptide was 
a relatively poor substrate for the PAK-1 fragment compared 
with PKM (&fold difference). 
The catalytic fragment of  PAK-1 phosphorylated  protamine 
sulfate a t  a rate 34 times slower than  that for PKM despite the 
fact  that  the protamine kinase activity of intact PAK-1 was 
comparable to  that of  PKM (Table 11). Also, the catalytic  frag- 
ment of  PAK-1 was severalfold less effective than PKM in  the 
phosphorylation of the histone H1-enriched fraction (Sigma 
4"p kDa R 
66 
45 
c .- 59 60  61  62 63 
E 
'D 
\ 
a, 
L 
L 
x 0  20 40 60  80  
W 
48 50 52 
0 20 40 60 80  
Fract ion Number 
PAK-1 and PKC (PKM) on Mono Q. Preparations of the  trypsin- 
FIG. 3. Chromatography of trypsin-generated fragments of 
generated  active  fragments of  PAK-1 (0) and PKC (0) eluted from the 
S6 peptide  affinity column were  chromatographed on Mono Q (FPLC); 
0.5-ml fractions were collected and assayed for S6-(229-239) peptide 
kinase activity. Separate  preparations of PAK-1 fragments were chro- 
matographed  in A and B. In A, column fractions  59-63  were also ana- 
lyzed by  10% SDS-PAGE and  silver-stained (inset ). In B ,  the PAK-1 and 
PKC (PKM) active fragments were generated and chromatographed 
under  identical conditions. 0.5-ml column fractions were collected. Frac- 
tions  48,50,  and  52  were  analyzed b  SDS-PAGE (as described for A )  for 
polypeptides associated  with PKM activity (inset). 
Type 111-S histone  fraction), thus explaining the absence of a 
clearly defined peak of  PAK-1 activity when the Chl-Sephadex 
chromatographic  fractions were screened  with this  substrate 
(see Fig. la). Both PAK-1 and PKM displayed similarly low or 
no activity  toward  Sigma Type 11-AS mixed histones, phosvitin, 
casein, or the  H4443-49) analogue of histone H4 (Table 11) (13). 
The  substrate specificities for the cardiolipin-activated 
PAK-1 and  the purified  catalytic fragment of the enzyme were 
generally similar. Exceptions were protamine sulfate, which 
was phosphorylated  relatively well  by the cardiolipin-activated 
enzyme, and the GS41-12) peptide substrate, which was a 
relatively better  substrate for the catalytic  fragment (Table 11). 
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TABLE I1 
Comparison of substrate specificity of P M - 1  
PAK-1 (post-protamine-CH-Sepharose pool),  PAK-1 active fragments 
(consisting predominantly of the 55-kDa fragment; Fig. 3A), and protein 
kinase M (post-Mono  Q;  Fig. 3B) were assayed with synthetic peptide 
(S64229-239) at 30 and all other peptides at 100 w) and protein (1 
mg/ml) substrates for 10 min at 30  "C as described under "Experimental 
Procedures." Relative phosphotransferase activity refers to the activity 
as  a percentage of that obtained from the S6-(229-239) substrate  (in  the 
case of PAK-1 minus trypsin, the activities are expressed as percentages 
of the PAK-1 plus trypsin S6-(229-239) activity). The absolute activities 
for the trypsin- and cardiolipin-activated forms of PAK-1 with the S6- 
(229-239) substrate were 26 and 25.5  pmol/min,  respectively.  The ab- 
solute activities (100%) of the purified catalytic fragments of PAK-1 and 
PKM were  25 and 27.5  pmol/min,  respectively. 
Relative uhosuhotransferase activitv 
564229-239)  100  21.5 
Histone 11-AS 
Histone 111-S 
4.7  2.7 
8.3 7.1 
Phosvitin 1.5 1.5 
Casein 0 0 
Protamine sulfate 30.4  50.8
Myelin basic protein 11.1  8.9 
GS-(l-12) analogue 165.0 12.1 
29.3  6.6 
6.3 2.7 
EGFR-(650-658) 
H4443-49) 
CL, cardiolipin; ND, not determined. 
100 
9.3 
4.5 
1.6 
0 
ND 
44.4 
176.0 
ND 
20.6 
100 
11.5 
9.7 
1.4 
0 
ND 
2.1 
19.3 
1.0 
321 
100 
38.4 
12.3 
0.8 
1.3 
ND 
71.4 
47.2 
42.6 
0 
. I  1 10 100 1000 
Phospholipid (pglml) 
FIG. 4. Dose-response curve for phospholipid activation of 
PAK-1. The activity of purified liver PAK-1 was assayed with the S6- 
(229-239) peptide substrate  in  the presence of various concentrations of 
phospholipids as described under "Experimental Procedures." Activity 
is relative to  that obtained in  the absence of phospholipids (100%). The 
z axis refers to the concentration of individual phospholipiddmilliliter 
of reaction mixture: cardiolipin (01, phosphatidylglycerol (01, phos- 
phatidylinositol (m), phosphatidic acid ( 0 ,  phosphatidylserine (A), and 
phosphatidylcholine (A). 
Inhibitors of PM-1-PAK-1  exhibited  differential  sensitivi- 
ties to a range of metal ions. While the enzyme exhibited a 
characteristic M e  dependence  for a protein  kinase,  with an 
optimal Mg2' ion  concentration in the range of  2-5 mM (data  not 
shown), other divalent metal ions were inhibitory. Both the 
basal  and  protease-activated  kinase  activities  were  inhibited 
by  Ca2+, with an IC,,  of 1.2 mM for the trypsin-activated PAK-1 
(Table 111). PAK-1 activity was inhibited by >98% by 10 mM 
Mn2+, Cu2+, Co2+, or Zn2+ ions  (data  not  shown).  The  enzyme  was 
also  sensitive  to  inhibition  by  NaF,  glycerophosphate  (mixed a- 
and p-isomer  ions),  staurosporine,  and H-7 (1-(5-isoquinolinyl- 
sulfonyl)-2-methylpiperazine), with IC,, values of 30 mM, 54 
mM, 30 nM, and 180 m, respectively  (Table 111). 
PAK-1 trypsin-activated S6 peptide  kinase  activity  was  also 
found  to  be  very  sensitive  to  inhibition  by  polyarginine  and  less 
sensitive to polylysine, with IC,, values of 0.3 and 3 pg/ml, 
respectively  (Table 111). However,  PAK-1  protamine  sulfate ki- 
nase activity was appreciably less sensitive to polyarginine, 
with an IC,, of 8 pg/ml,  and  was  insensitive  to  inhibition  by 
TABLE I11 
Effects of inhibitors on P M - 1  
Trypsin-activated PAK-1 was assayed for S6-(229-239) peptide ki- 
nase activities in the presence of various modifiers. For comparison, the 
IC,, for PKC-a-(19-31) inhibition of rat PKM with the S6-(229-239) 
substrate was 8 PM. PAK-1 (intact enzyme) was assayed for protamine 
kinase activity without trypsin treatment. The concentration of inhibi- 
tor at which the activity was  reduced by  50% is given as  the IC5,,, 
Modifier IC50 
S6-(229-239) substrate 
Sodium glycerophosphate 
NaF 30 mM 
54 mM 
CaC1, 1.2 mM 
0.8 mM 
Staurosporine 
H-7 
30 nM 
180 1 1 ~  
Polyarginine 0.3 pg/ml 
Polylysine  3.0  pg/ml 
Polyarginine 8 pg/ml 
Polylysine No inhibition 
PKC-a-(19-31) 
Protamine substrate 
(up to 100 pg/ml 
tested) 
TABLE IV 
Sequences of tryptic peptides derived  from  the 116-kDa P M - 1  and its 
active catalytic fragments 
Tryptic peptides derived  from the in-gel digest of the 116-kDa PAK-1 
(peptides 1-4)  and from the tryptic digest of the 55-kDa catalytic frag- 
ment of PAK-1 (peptides 1-7) were aligned with the protein kinase 
subdomains (I-XI) as described by Hanks and Quinn (36). Tryptic  pep- 
tides 2 and 6 7  were  also  derived  from pure preparations of the 43-kDa 
fragment. The 93 amino acid residues contained in the PAK-1 catalytic 
domain peptides 2 and 4-7 displayed an overall identity of 58%  to the 
corresponding rat PKC-a sequences (37). The residues shown in bold- 
face are identical to  the corresponding PKC-a  sequence. 
Peptide Sequence Kinase subdomain 
1 DFDFVAGGY 
2 LDNLLLDTEGYVK VI 
3 TLDWDALLAR 
4 VLLSEFHSSGELFAIK 
5 
1-11 
IADFGLCK VI1 
6 TSTF'CGTPEFLAPEVLTDTSYTR VI11 
7 AVDWWGLGVLLYEMLVGESPFPGD Ix 
ture  (Table 111). A comparison of the  inhibitor  dose-response 
curves  for the active  catalytic  fragments of PAK-1 and  brain 
PKC  with the 564229-239)  substrate  indicated that PAK-1  was 
100-fold less sensitive to inhibition by the PKC-a-(19-31) 
pseudosubstrate  inhibitor  peptide (241, with IC,, values of 800 
and 8 p~ for PAK-1 and PKM, respectively  (Table 111). 
Amino  Acid Sequence Analysis of Dyptic  Fragments of PAK- 
1-Automated  sequence  analyses of tryptic  fragments of PAK-1 
established that the active  catalytic  fragment of the enzyme 
generated  by  limited  proteolysis  was in fact  derived  from the 
116-kDa  polypeptide and that the enzyme  was  structurally  dis- 
tinct  from  any  previously  described  protein  kinase  (Table IV). 
The  sequences of several  tryptic  peptides  generated  from the 
116-kDa PAK-1 polypeptide  excised  from  SDS-polyacrylamide 
gels  and  purified  by  reversed-phase HPLC, although  unique, as 
determined by screening the SwissProt  and  GeneBank  data 
bases,  could  be  aligned  with  the  catalytic  domains of known 
protein  kinases  (Table  IV) (36). The  same  and  additional  tryptic 
peptides  originating  from  the  catalytic  domain  were  also  gen- 
erated  from  purified  preparations of the catalytically  active 55- 
and  43-kDa  PAK-1  fragments  (Fig. 3 A ) ,  confirming that these 
fragments are tryptic  variants of the  parent  116-kDa PAK-1 
(Table N). The  tryptic  peptide  sequences that aligned  with the 
catalytic  domain  consensus  sequence  (36)  displayed  the great- 
est homology to  the PKC  isoenzymes,  ranging  from 50-58%; for 
polylysine at concentrations up  to  100  pg/ml of reaction  mix-  example, the PAK-1 tryptic  peptides in Table IV displayed an 
~~ 
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overall identity of 58% to  the corresponding region of rat PKC-a 
(37). 
DISCUSSION 
PAK-1 is appreciably larger (apparent M, of 116,000) than 
any of the defined PKCs, the  largest being PKC-E, with a M, of 
83,474 (apparent M, of 95,700 by SDS-PAGE) (38). The  amino 
acid sequences of its tryptic peptides, although  related, do not 
match exactly the sequences of any previously defined protein 
kinases found by searching  the  SwissProt  and  GeneBank  data 
bases (36, 39). The sequence comparisons showed that the 
PAK-1 tryptic sequences  resembled the sequences of the PKC 
isoenzymes (50-58% sequence identity) to a greater degree 
than  the corresponding  regions of other protein kinases (<45% 
identity),  suggesting  that PAK-1 might  be  related to the PKC 
subfamily. 
PAK-1 is >lOO-fold less sensitive than the brain PKCs to 
inhibition by the PKC-a-(19-31) pseudosubstrate  inhibitor pep- 
tide (Table 111) (24) and displays distinct  substrate specificity. 
In particular, PAK-1 is relatively  more  active with  the glycogen 
synthase peptide analogue  and  less active with histone H1 and 
the EGFR-(650-658) peptide substrates. However, PAK-1 and 
brain PKC share  similar phosphorylation site specificity deter- 
minants  within  the S6-(229-239) substrate,  particularly  with 
respect to  the beneficial influence of arginine  residues closely 
situated on both sides of the preferred SeP36 phosphorylation 
site (19, 20). The affinity of the enzyme for sequences  contain- 
ing  arginine  residues  was also reflected in  the  high activity of 
intact PAK-1 with  the  protamine  sulfate  substrate as well as 
the relatively low IC,, for inhibition of S6-(229-239) kinase 
activity by polyarginine, even though  the  inhibitor  was less 
effective with  the  protamine  substrate (Table 111). 
Rat liver PAK-1 can also  be distinguished from other prote- 
ase-activated  protein kinases capable of phosphorylating ribo- 
somal  protein S6. Rabbit  reticulocyte PAK I1 (11) displays  simi- 
lar activity  toward ribosomal protein S6 in vitro (11, 12) and 
sensitivity  to inhibition by Ca2+ (15,26), but unlike  liver PAK-1, 
is activated by a mixture of phosphatidylserine and diolein (151, 
has a relatively high K,,, for ATP of 56 p~ (26) compared with 12 
p~ for PAK-1, and is relatively  more  active with  histone H1 as 
substrate.  The lymphosarcoma PAK (13) and a similar enzyme 
from human  placenta (40-421, which also  phosphorylates ribo- 
somal protein S6, can be distinguished from PAK-1 by their 
preference  for the  histone H4443-49) peptide  substrate, which 
is relatively a very poor substrate for PAK-1 (Table 11). While 
S6H4 kinase resembles PAK-1 in  that  it phosphorylates the 
S6-(229-249) analogue and is unaffected by the PKC-a-(19-31) 
inhibitor (40, 411, it is smaller (66 kDa) (42) and is relatively 
more effective with both histone H4 and myelin basic  protein 
substrates (40, 41). 
So far, we have been unable  to  demonstrate  the phospho- 
rylation of protein  substrates for PAK-1 other  than ribosomal 
protein S6 in liver extracts,  indicating a narrow  range of sub- 
strate specificities. The preferred  phosphorylation site for 
PAK-1 in S6 is Ser236 (14, 201, which is also  phosphorylated in 
vivo (2,6,32,33) and which is the  initial  site phosphorylated by 
Xenopus S6 kinase I1 in  the ordered  sequence of phosphoryla- 
tion sites on 40 S ribosomal subunits (3). While PAK-1 does  not 
efficiently catalyze the phosphorylation of sites other than 
Sel.256 (201, the possibility remains  that PAK-1 contributes  to S6 
phosphorylation in  vivo in  other physiological contexts. 
The favorable kinetics of phosphorylation of protamine  sul- 
fate by intact PAK-1, without proteolytic or cardiolipin  activa- 
tion (K, = 3.6 PM), indicate that  this  substrate overcomes in- 
tramolecular inhibition of the catalytic activity, possibly due  to 
displacement of an  intramolecular inhibitory sequence from 
the active site of the enzyme by the highly basic protamine (24, 
39). The  arginine-rich S6-(229-239) substrate also appears  to 
be able  to overcome this form of competitive inhibition at  high 
substrate concentrations. The need to overcome the  intramo- 
lecular competitive  inhibition would explain the relatively  high 
Km observed with this  peptide  substrate  in  the absence of en- 
zyme activation (110 PM) compared with  the low K, for the 
catalytic  fragment (3.4 p ~ )  (20) or cardiolipin-activated  enzyme 
(3.6 PM). Protamine  sulfate  can also overcome the  normal  re- 
quirements for PKC activation (39,43,44). However, a striking 
difference between PAK-1 (Table 11) and  the PKCs (16) is  the 
relative  inability of the purified  catalytic fragment of PAK-1 to 
phosphorylate protamine compared with the PKM activity. 
This implies an influence of the proteolytically cleaved regula- 
tory  domain of PAK-1 on substrate specificity analogous to  that 
reported for PKC-E (16).  A further complexity is that  the rela- 
tively high activity of the cardiolipin-activated enzyme with the 
protamine substrate, compared with the low activity of the 
catalytic  fragment  with  this  substrate,  suggests  that  the favor- 
able influence of the  regulatory domain on protamine phospho- 
rylation  is  retained  in  the phospholipid-activated enzyme. 
The  moderate  abundance of PAK-1 in liver suggests  an im- 
portant role in  hepatic regulation. Activation through  interac- 
tion with some lipophilic regulator  seems likely given the re- 
semblance  between  several properties of PAK-1 and  the PKCs 
(17, 39). Consistent with this possibility is the activation of 
PAK-1 by  low concentrations of cardiolipin and, to varying de- 
grees, several  other acidic phospholipids. However, the  unre- 
sponsiveness of the PAK-1 S6 peptide kinase activity to various 
combinations of phosphatidylserine, phorbol ester, and Ca2+ 
distinguishes PAK-1 from the previously defined members of 
the PKC family, even after  taking  into account the differential 
sensitivities of the individual PKC isoenzymes to  the different 
ligands (17,34,39,43,44). Cardiolipin  also activates  the PKCs, 
although  the  sensitivities of individual PKC isoenzymes to  this 
phospholipid varies considerably, with little activation of the 
classic PKC-a,  PKC-PII, and PKC-y (45) compared with rela- 
tively good activation of PKC-E (38, 46) and PKC-C (43). The 
physiological significance of the cardiolipin effects in vitro is 
unclear given the almost exclusive location of the lipid within 
the  inner mitochondrial  membrane. While the possibility of a 
role of PAK-1 in mitochondrial regulation warrants further 
investigation, potential regulatory roles in other subcellular 
locations must also  be considered, possibly involving other lipid 
activators of PAK-1 such as phosphatidic acid, which has  re- 
cently been implicated in a range of signal  transduction pro- 
cesses (e.g. Ref. 47). 
The isolation, partial structural characterization, and ob- 
served  activation of PAK-1 by phospholipids should provide the 
basis for elucidating  the physiological role(s) of this enzyme in 
future investigations. 
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